Nissan Medical Industries Website, Blog & Press Pages - aVenture Research
Nissan Medical Industries
Nissan Medical Industries manufactures and markets spunlace non-woven fabrics for consumer, medical, automotive, infrastructure and hygienic applications.
Nissan Medical Industries reports **ILS 133.56 million in Q2 sales**, down from ILS 166.18 million year-over-year. The company’s net income rises to **ILS 6.54 million** (vs. ILS 3.07 million) while earnings per share (basic/diluted) increase to **ILS 0.71** from ILS 0.35. Results cover the second quarter and first half of fiscal 2026.
Nissan Medical Industries reports **ILS 146.08 million in Q1 sales**, a decline from **ILS 157.88 million** in the same period last year. The company also reports a **net loss of ILS 2.35 million**, widening from a **net loss of ILS 1.98 million** in Q1 2025. The results reflect continued financial challenges in the first quarter of 2026.
Nissan Medical Industries reports **ILS 651.78 million in sales** for the full year ended December 31, 2025, a decline from **ILS 664.08 million** in the prior year. The company’s net income also decreased to **ILS 4.17 million**, down from **ILS 7.91 million** in 2024. The results reflect a contraction in both revenue and profitability for the medical devices manufacturer.
Nissan Medical Industries reports **ILS 179.99 million in Q3 sales**, up from ILS 167.23 million year-over-year. The company achieves **ILS 2.67 million net income**, a significant increase from ILS 0.04 million in the same period last year. Basic and diluted earnings per share from continuing operations rise to **ILS 0.3**, compared to ILS 0.01 annually.
Nissan Medical Industries reports Q2 2025 sales of **ILS 166.18 million**, a slight decline from **ILS 167.66 million** in the same period last year. The company’s net income rises to **ILS 3.07 million** (up from **ILS 2.62 million**), with earnings per share increasing to **ILS 0.35** from **ILS 0.28** year-over-year. These results cover the six-month period ending June 30, 2025.